Gary S. Gillheeney - 01 Jun 2022 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
President and CEO, Director
Signature
/s/ William R. Kolb, Attorney-in-Fact
Issuer symbol
ORGO
Transactions as of
01 Jun 2022
Net transactions value
-$1,127,782
Form type
4
Filing time
03 Jun 2022, 16:51:38 UTC
Previous filing
31 May 2022
Next filing
01 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Options Exercise $93,542 +94,487 +24% $0.9900 492,729 01 Jun 2022 Direct
transaction ORGO Class A Common Stock Sale $521,568 -94,487 -19% $5.52 398,242 01 Jun 2022 Direct F1, F2
transaction ORGO Class A Common Stock Options Exercise $115,442 +116,608 +29% $0.9900 514,850 02 Jun 2022 Direct
transaction ORGO Class A Common Stock Sale $650,673 -116,608 -23% $5.58 398,242 02 Jun 2022 Direct F1, F3
transaction ORGO Class A Common Stock Options Exercise $35,877 +36,239 +9.1% $0.9900 434,481 03 Jun 2022 Direct
transaction ORGO Class A Common Stock Sale $200,402 -36,239 -8.3% $5.53 398,242 03 Jun 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -94,487 -38% $0.000000 152,847 01 Jun 2022 Class A Common Stock 94,487 $0.9900 Direct F5
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -116,608 -76% $0.000000 36,239 02 Jun 2022 Class A Common Stock 116,608 $0.9900 Direct F5
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -36,239 -100% $0.000000* 0 03 Jun 2022 Class A Common Stock 36,239 $0.9900 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $5.66, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 100% of the shares subject to the option are fully vested and exercisable.